The GJA1 antibody targets the gap junction protein alpha 1. commonly known as connexin 43 (Cx43), encoded by the *GJA1* gene. Gap junctions are intercellular channels that facilitate direct communication between adjacent cells by allowing the passage of small molecules, ions, and electrical signals. Cx43. a member of the connexin family, is widely expressed in tissues such as heart, skin, brain, and blood vessels, playing critical roles in embryonic development, tissue homeostasis, and synchronized cellular activities.
GJA1 antibodies are essential tools for studying Cx43 expression, localization, and function in both physiological and pathological contexts. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate conditions linked to Cx43 dysregulation, including cardiovascular diseases (e.g., arrhythmias, myocardial infarction), cancer (e.g., tumor metastasis), skin disorders, and neurological abnormalities. Research also focuses on Cx43's involvement in wound healing, inflammation, and stem cell differentiation.
Commercially available GJA1 antibodies are typically raised against specific epitopes of human Cx43 but may cross-react with homologs in other species due to high sequence conservation. Researchers must validate antibody specificity, considering post-translational modifications (e.g., phosphorylation) that alter Cx43's mobility or antigenicity. Dysfunctional Cx43 has been implicated in rare genetic disorders like oculodentodigital dysplasia, underscoring the antibody's diagnostic and research relevance.